Drug Profile
IMX 942
Alternative Names: IMX942Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Inimex Pharmaceuticals
- Class Peptides
- Mechanism of Action Immunostimulants; Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Nosocomial infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Nosocomial-infections(In volunteers) in Canada (IV)
- 27 Apr 2009 Phase-I clinical trials in Nosocomial infections in Canada (IV)